Stocktoria
Upstream Bio, Inc. UPB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-10-11
Upstream Bio, Inc. statistics & valuation
Market cap$322.2M
P / B0.9×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating margin | -5618.8% | -3281.2% | -1685.5% |
| Net margin | -5026.0% | -2650.0% | -862.9% |
| FCF margin | -4675.5% | -2518.3% | -1599.6% |
| Return on assets | -40.5% | -13.0% | -17.5% |
| Return on equity | -42.2% | -13.4% | 16.7% |
| Current ratio | 26.15 | 44.63 | 17.96 |
| Revenue growth | 20.4% | -0.4% | — |
Source: SEC EDGAR filings · CIK 0002022626 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.